In a report issued on June 13, Jonathan Komp from Robert W. Baird maintained a Hold rating on Rocky Brands (RCKY – Research Report). The company’s shares closed last Friday at $31.77, close to its 52-week low of $31.26.
According to TipRanks.com, Komp is a 5-star analyst with an average return of 10.7% and a 46.9% success rate. Komp covers the Consumer Goods sector, focusing on stocks such as Canada Goose Holdings, Wolverine World Wide, and Columbia Sportswear.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocky Brands with a $78.00 average price target.
Based on Rocky Brands’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $167 million and net profit of $7.34 million. In comparison, last year the company earned revenue of $87.67 million and had a net profit of $4.49 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocky Brands, Inc. engages in the design, manufacture, and marketing of footwear and apparel. Its brand includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and Michelin. It operates through the following segments: Wholesale, Retail, and Military. The Wholesale segment distributes its products through retail stores. The Retail segment includes direct sales of its products to consumers through e-commerce websites, third party marketplaces, and Rocky outlet store. The Military segment focuses on the bidding of footwear contracts with the U.S. military. The company was founded in 1932 and is headquartered in Nelsonville, OH.
Read More on RCKY:
- Robert W. Baird Sticks to Its Buy Rating for F45 Training Holdings (FXLV)
- Xponential Fitness (XPOF) Receives a Buy from Robert W. Baird
- Deutsche Bank Remains a Buy on Canadian National Railway (CNI)
- Deutsche Bank Keeps a Hold Rating on Norfolk Southern (NSC)
- LifeSci Capital Thinks VYNE Therapeutics’ Stock is Going to Recover